Research programme: melanocortin-4 receptor agonists - LION bioscience/Novartis
Alternative Names: Melanocortin-4 receptor agonists - LION bioscience/NovartisLatest Information Update: 01 Dec 2003
At a glance
- Originator Novartis; SYGNIS Pharma
- Class
- Mechanism of Action Melanocortin type 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus; Obesity
Most Recent Events
- 01 Dec 2003 Discontinued - Preclinical for Diabetes mellitus in USA (unspecified route)
- 01 Dec 2003 Discontinued - Preclinical for Obesity in USA (unspecified route)
- 06 Aug 2003 No development reported - Preclinical for Diabetes mellitus in USA (unspecified route)